Eye surgery

US Eye Chief Medical Officer Dr. Kerry Solomon Honored with AECOS Award

Retrieved on: 
Tuesday, March 12, 2024
General Health, Surgery, Other Health, Health, Optical, Retina, Congress, Education, Eye, Refractive surgery, Physician, ASCRS, Patient, Research, Cataract, Surgeon, Society, Southeastern United States, Eye surgery, Multimedia, FDA, Ophthalmology, Medical device

View the full release here: https://www.businesswire.com/news/home/20240312937973/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312937973/en/
    Kerry Solomon, M.D., US Eye Chief Medical Officer (Photo: Business Wire)
    Speaking of the Dulaney Award, Dr. Solomon comments, “I am incredibly proud to be the recipient of this year’s Dulaney Award.
  • Dr. Solomon currently serves as the Chief Medical Officer at US Eye, a physician-led network of eye care practices across the Southeastern United States and is a LASIK and Laser Cataract Surgeon at Carolina Eyecare Physicians in Mount Pleasant, South Carolina.
  • To that end, Dr. Solomon truly embodies the purpose of the AECOS Dulaney Award.
  • We are proud to work beside him and experience his impactful contributions firsthand,” said Brad Logan, CEO of US Eye.

Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair

Retrieved on: 
Monday, February 26, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Ophthalmology, FDA, Optometry, Physician, MBA, Pharma, Drainage, Pulse, Eye surgery, Telecanthus, Patient, MAB, Congress, Chair, Pharmaceutical industry

Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).
  • Dr. Donnenfeld joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® canalicular gel.
  • The FDA-cleared hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
  • “Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market.

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Thursday, February 1, 2024
Principal, Public key certificate, Cordis, MD, Society, FDA, Columbia University, International Society, Book, Family, American Academy, Cataract, Don, Lehigh University, Culture, University, Refraction, ASCRS, Refractive surgery, Growth, American College, Mount Sinai Medical Center, Publication, Wills Eye Hospital, CFO, Congress, Therapy, Eye surgery, MBA, Executive, Accounting

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Monday, May 1, 2023
Speaker, IOP, San Diego Convention Center, Exhibition, Physician, MBA, ASCRS, Research, MIGS, Consultant, Eye surgery, Intraocular pressure, Telecanthus, Meibomian gland dysfunction, Ophthalmology, Gland, OMNI, Lens (vertebrate anatomy), LHT, Medication, MGD, Safety, Medical device, Pharmaceutical industry, Dentistry, Food delivery, MD, Patient

The OMNI Surgical System technology facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma.

Key Points: 
  • The OMNI Surgical System technology facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma.
  • He continued, "This year is truly unique given the breadth and sheer strength of our clinical data across our product portfolio.
  • Glaucoma Medication Use in Patients with a Mild Glaucoma Severity After Receiving MIGS: An Academy IRIS® Registry Analysis oral presentation by Michael Mbagwu, MD.
  • Impact of TearCare on reading speed in patients with dry eye disease oral presentation by Preeya Gupta, MD.

Study Shows Novel Flavoprotein Fluorescence Measure is Correlated with Age-Related Macular Degeneration (AMD) Stage

Retrieved on: 
Wednesday, February 8, 2023
Medical Devices, Health, Diabetes, Health Technology, Optical, Biotechnology, Ophthalmic Surgery, Lasers and Imaging Retina, Patient, AMD, GA, Flavoprotein, Eye surgery, ATP, Institutional review board, Intermediate, Apoptosis, Cell death, Mitochondrion, Macular degeneration, Laser, Mitochondrial disease, FPF, Geographic atrophy, Medical imaging

By quantifying the degree of retinal oxidative stress and mitochondrial dysfunction, these findings suggest that the novel FPF measure can categorize AMD patients by stage, which may better elucidate the underlying pathophysiology of AMD.

Key Points: 
  • By quantifying the degree of retinal oxidative stress and mitochondrial dysfunction, these findings suggest that the novel FPF measure can categorize AMD patients by stage, which may better elucidate the underlying pathophysiology of AMD.
  • Intermediate, geographic atrophy, and neovascular AMD correlated with significantly increased FPF intensity, while all AMD stages correlated with increased FPF heterogeneity.
  • “These findings suggest that mitochondrial function plays an important role in the progression of AMD,” said Dr. Singh.
  • The OcuMet Beacon is currently being used at Cole Eye Institute under Institutional Review Board.

Verana Health Study Using Curated Real-World Data to Replicate Phase III Ophthalmology Clinical Trial Published in OSLI Retina

Retrieved on: 
Wednesday, January 18, 2023
Laser, Eye surgery, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, RWD, VIEW, IRIS, FDA, Regeneron Pharmaceuticals, Research, Isabella Tree, Manuscript, Machine Intelligence Research Institute, Food, Patient, American Academy of Ophthalmology, American Academy, SAN, III, ARVO, Annual general meeting, Medical imaging, Pharmaceutical industry, Retina, Ophthalmology

SAN FRANCISCO, Jan. 18, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced that medical journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina has published a manuscript detailing innovative research showing how curated, de-identified real-world data (RWD) from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) was used to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology—the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.

Key Points: 
  • Verana Health's study is the first to use RWD to replicate outcomes in an ophthalmology phase III pivotal trial.
  • Following the ARVO presentation, Verana Health researchers conducted modeling to determine whether undetected biases had influenced the data.
  • The Verana Health study demonstrates that researchers can replicate Phase III trial outcomes using curated, de-identified RWD that are fit-for-use.
  • To request a copy of the recently published study, conducted by Dr. Leng and a team of Verana Health researchers, visit: https://info.veranahealth.com/view1-view2-manuscript .

OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease

Retrieved on: 
Wednesday, October 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, Blood, DME, ClinicalTrials.gov, OCT, Female, Disease, Therapy, Biological activity, US1, Growth, Diabetic retinopathy, RGD, Eye surgery, Patient, Severe cognitive impairment, Eye, Treatment, CRT, Diabetes, Retinopathy, Toxicity, Research, Adult, Safety, Ageing, DR, American Academy, Injection, Clinical trial, DRSS, OCB, VEGF, Laser, Male, American Academy of Ophthalmology, Pharmaceutical industry, Ophthalmology, Retina

The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.

Key Points: 
  • The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.
  • Based on these findings, the Phase 2 DR:EAM study is underway to evaluate safety and efficacy of OTT166 in diabetic retinopathy.
  • In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.
  • The Phase 1b DR/DME clinical trial (NCT02914613) was a prospective, randomized, double-masked, first-in-human study of OTT166 (formerly designated SF0166) eye drops in patients with DR/DME, i.e.

Beyeonics Vision has completed the CE Mark registration for its Beyeonics One™ ophthalmic exoscope

Retrieved on: 
Thursday, September 29, 2022
Eye surgery, 3D, AR, Ophthalmology, CE marking, Paola Lattus, Tel Aviv Sourasky Medical Center, Partnership, Patient, Aircraft, Eye, CEO, BVI, Technology, Surgeon, Virtual reality, Orthopedic surgery, VR, Medical device

HAIFA, Israel, Sept. 29, 2022 /PRNewswire/ --Beyeonics Vision, a medical device company, announced today that it has completed the registration process and received the CE Mark in Europe for its patented Beyeonics One, a fully digital 3D surgical visualization platform.

Key Points: 
  • HAIFA, Israel, Sept. 29, 2022 /PRNewswire/ --Beyeonics Vision, a medical device company, announced today that it has completed the registration process and received the CE Mark in Europe for its patented Beyeonics One, a fully digital 3D surgical visualization platform.
  • The Beyeonics One exoscope provides high magnification and clear, detailed image of the surgical field with zero perceived latency.
  • Ron Schneider, CEO and Co-founder of Beyeonics: "We are very proud of obtaining a CE mark that will allow us to bring our evolving platform technology to Europe.
  • Beyeonics Vision Ltd. is developing and manufacturing the Beyeonics one, delivering advanced visualization and unconstrained performance to ophthalmic surgeons.

Vitreoretinal Surgery Devices Market to Witness Dynamic Growth at an Increased CAGR of 7.73% Reaching USD 2.45 Billion by 2026, Research Report | DelveInsight

Retrieved on: 
Monday, March 28, 2022
Paragon, Bausch & Lomb, Therapy, CAGR, Diabetic retinopathy, Diabetes, Uveitis, Forecasting, Freeflow, International, Company, Silicone, Gas, USD, Retina, Eye, Vitreous hemorrhage, Growth, Macular degeneration, Government, Awareness, FDA, Retinal detachment, Partnership, Johnson & Johnson Vision, FCI, Eye surgery, LAS, Prevalence, Epiretinal membrane, COVID-19, Dentistry, Pharmaceutical industry, Hospital, Health insurance, BVI

LAS VEGAS, March 28, 2022 /PRNewswire/ -- DelveInsight's Vitreoretinal Surgery Devices Market Insights and Forecast report provides the current and forecast Vitreoretinal Surgery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Vitreoretinal Surgery Devices Market. 

Key Points: 
  • LAS VEGAS, March 28, 2022 /PRNewswire/ --DelveInsight's Vitreoretinal Surgery Devices Market Insights and Forecast report provides the current and forecast Vitreoretinal Surgery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Vitreoretinal Surgery Devices Market.
  • Some of the key takeaways from the Vitreoretinal Surgery Devices Market report:
    As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth in the Vitreoretinal Surgery Devices market.
  • DelveInsight analyzes that the Global Vitreoretinal Surgery Devices Market was valued at USD 1.57 billion in 2020, growing at a CAGR of 7.73% during the forecast period from 2021 to 2026 to reach USD 2.45 billion by 2026.
  • However, on the other hand, postoperative complications of Vitreoretinal Surgery and retinal toxicity of medical devices used during Vitreoretinal Surgery may be certain impeding factors to Vitreoretinal Surgery Devices market growth.

Kubota Vision Initiates PBOS Prospective Study in Patients

Retrieved on: 
Tuesday, January 18, 2022
Optical, Health, Clinical Trials, Medical Devices, Research, Stargardt disease, Patient, Severe cognitive impairment, Cornea, Retina, Hope, Eye surgery, Diabetic retinopathy, AMD, DME, CEO, HIV disease progression rates, MHealth, View, All India Ophthalmological Society, Society, Artificial intelligence, Company, Association, Hospital Insurance and Diagnostic Services Act, Pharmacology, Doctor of Philosophy, MD, OCT, Optical coherence tomography, Glaucoma, Association for Research in Vision and Ophthalmology, Hospital, Physician, Medicine, Medical device, Medical imaging, Ophthalmology, PBOS, Kubota Vision Inc., PBOS, KUBOTA VISION INC.

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT*1) device.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT*1) device.
  • The PBOS operates on the same principle as OCT devices used at hospitals but is developed so patients can operate it by themselves at home.
  • Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.